0001193125-26-380228 | 10-Q | XBRL Viewer

Print Document

Preferred Stock Tranche Liability (Additional Information) (Details) - Series B Redeemable Convertible Preferred Stock [Member] - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	6 Months Ended
	Jan. 31, 2025	Jun. 30, 2025
Class of Stock [Line Items]
Fair value upon settlement		$ 6.8
Net loss included in earnings		$ 0.2
Fair Value Per Share	$ 1.55

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1

Reference 27: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
us-gaap:NetIncomeLoss	$ (39,343)	$ (29,590)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	1,378	1,025
Depreciation expense	488	350
Net accretion of discounts on marketable securities	(346)	(1,238)
Non-cash lease expense	795	632
Change in fair value of preferred stock tranche liability	0	170
Loss on disposal of property and equipment	0	6
Write-off of deferred offering costs	0	393
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	972	1,106
Accounts payable	3,159	2,174
Accrued and other current liabilities	(1,124)	(1,335)
Operating lease liability	(936)	(175)
Other non-current assets	25	(215)
Net cash used in operating activities	(34,932)	(26,697)
Cash flows from investing activities
Maturities of marketable securities	77,900	37,250
Purchases of marketable securities	(48,174)	(138,823)
Purchases of property and equipment	(361)	(1,886)
Net cash provided by (used in) investing activities	29,365	(103,459)
Cash flows from financing activities
Proceeds from issuance of common stock upon exercise of stock options	42	143
Payments of deferred offering costs	(1,839)	(371)
Net cash (used in) provided by financing activities	(1,797)	141,966
Net change in cash, cash equivalents and restricted cash	(7,364)	11,810
Cash, cash equivalents and restricted cash at the beginning of the period	40,597	31,239
Cash, cash equivalents and restricted cash at the end of the period	33,233	43,049
Supplemental disclosures of noncash investing and financing activities
Deferred offering costs in accounts payable and accrued and other current liabilities	709	4
Vesting of early exercised stock options	78	67
Property and equipment purchases in accounts payable	6	183
Accretion of redeemable convertible preferred stock to its redemption value	0	271
Right-of-use asset obtained in exchange for operating lease liability	0	5,771
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	32,829	42,645
Restricted cash	404	404
Total cash, cash equivalents and restricted cash	33,233	43,049
Series B
Cash flows from financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs	0	52,465
Supplemental disclosures of noncash investing and financing activities
Settlement of preferred stock tranche liability upon issuance of Series B redeemable convertible preferred stock	0	6,808
Series C
Cash flows from financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs	$ 0	$ 89,729

Common Stock (Additional Information) (Details) - $ / shares	Jun. 30, 2026	Dec. 31, 2025
Stockholders' Equity Note [Abstract]
Authorized shares of common stock	284,023,000	284,023,000
Common Stock Issued	4,529,100	4,507,108
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common stock, shares outstanding	4,529,100	4,507,108

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

License Agreements

6 Months Ended

Jun. 30, 2026

Research and Development [Abstract]

License Agreements

Alamar Platform License Agreement

On June 1, 2023, the Company and Alamar Biosciences, Inc. (“Alamar”) entered into a Platform License Agreement, which was subsequently amended and restated (as amended and restated, the “Alamar Platform License Agreement”). Under the Alamar Platform License Agreement, Alamar granted the Company a worldwide, non-transferable, sublicensable license to use the antibody engineering platform developed by or on behalf of Alamar (the “ATTOBODY Platform”) within the therapeutic field. The license is exclusive with respect to Alamar patents and patent applications and non-exclusive with respect to Alamar know-how.

In connection with the Alamar Platform License Agreement, the Company issued 2,428,646 shares of its common stock to Alamar as consideration for the license. Alamar is further entitled to development and regulatory milestone payments of up to $0.8 million and $3.5 million, respectively, or up to $4.3 million in the aggregate per product, on a product-by-product basis, as well as royalties on net sales of the covered products in the low-single-digit percentage range. Milestone payments are contingent consideration and are accrued when it becomes probable that the underlying milestone will be achieved. No milestone expense was recorded during the three and six months ended June 30, 2026 and 2025. The remaining milestones were considered not probable to be achieved as of June 30, 2026 and December 31, 2025. Royalties will be recognized as cost of sales when the covered products are sold and royalties are payable.

EndPath License Agreement and Equity Distribution

In July 2025, the Company entered into a license agreement with EndPath RadioTherapeutics, Inc. (formerly Isotovia Biosciences, Inc.) (“EndPath”) pursuant to which the Company granted EndPath an exclusive, worldwide license to certain of the Company’s ATTOBODY Platform technology for use in the development and commercialization of radioligand products (the “EndPath Agreement”). Under the EndPath Agreement, the Company is responsible for using its ATTOBODY Platform technology to generate and develop initial Attobodies directed to two initial targets.

As consideration for the license and related research and development obligations, the Company received 24,000,000 shares of EndPath common stock, of which 6,000,000 shares are subject to repurchase if specified conditions are not met, including the first accepted investigational new drug filing for a lead product, or certain termination events. The Company is also eligible to receive additional consideration under the EndPath Agreement of up to $14.5 million in development and regulatory milestone payments, up to $170.0 million in sales milestone payments, and low single-digit royalties on worldwide annual net sales of licensed products.

The EndPath arrangement represents a contract with a customer within the scope of ASC 606, Revenue from Contracts with Customers. The Company identified separate performance obligations for each of the two initial target programs, each consisting of the applicable license rights and related research and development services, together with related supporting activities.

As of June 30, 2026 and December 31, 2025, the Company recorded the fair value of 6,000,000 shares subject to repurchase as an asset with a corresponding customer deposit liability of $0.6 million, which was included in other non-current liabilities on the Company’s condensed consolidated balance sheets. The customer deposit liability remains outstanding until the repurchase option lapses, is exercised or is otherwise resolved. Upon receipt of the EndPath common stock, the Company concluded that its ownership interest met the criteria for equity method accounting. The Company elected the fair value option under ASC 825, Financial Instruments, and measured the EndPath common stock at fair value using an option pricing model based on EndPath’s Series A preferred stock.

The Company recognizes revenue using a cost-based input method over the estimated research term. The Company recognized $0.5 million and $0 of collaboration revenue under the EndPath Agreement during the three months ended June 30, 2026 and 2025, respectively. The Company recognized $0.5 million and $0 of collaboration revenue under the EndPath Agreement during the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026 and December 31, 2025, the contract liability related to the EndPath Agreement was $0 and $0.5 million, respectively, which was included in accrued expenses and other current liabilities on the Company’s condensed consolidated balance sheets.

The EndPath common stock was recorded upon receipt at fair value as an equity investment. In September 2025, the Company distributed 24,000,000 shares of EndPath common stock received as noncash consideration under the EndPath Agreement, with an aggregate carrying value of $2.4 million, to holders of the Company’s outstanding capital stock. Following the distribution, the Company no longer held any EndPath common stock. The distribution was accounted for as an in-kind dividend and reduced the Company’s equity investment in EndPath to zero. There was no gain or loss recognized as a result of the distribution, as there was no change in the fair value of the investment in EndPath during the short holding period between the initial valuation date and the distribution date.

On March 18, 2026, the Company entered into an amendment with EndPath related to the targets being developed. The amendment had no material impact on the condensed consolidated financial statements.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2026
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements and related disclosures are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The Company’s unaudited condensed consolidated financial statements include the accounts of its subsidiaries, and all intercompany transactions were eliminated upon consolidation. Prior to July 2025, the Company had no subsidiaries.
Reverse Stock Split	Reverse Stock Split On July 22, 2026, the board of directors approved, and on July 29, 2026, the Company effected, a reverse stock split of the shares of the Company’s outstanding common stock at a ratio of 1-for-9.29 (the “Reverse Stock Split”). The number of authorized shares and par value per share were not adjusted as a result of the Reverse Stock Split. All references to shares, options to purchase common stock, share amounts, per share amounts, and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. The shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. In addition, the conversion ratios for each series of the Company’s redeemable convertible preferred stock, which automatically converted into shares of common stock upon the closing of the Company’s IPO of common stock, were proportionally adjusted. No fractional shares were issued in connection with the Reverse Stock Split.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The condensed consolidated balance sheet as of December 31, 2025 was derived from the Company’s audited consolidated financial statements but does not contain all of the footnote disclosures from the consolidated financial statements. The accompanying unaudited interim condensed consolidated financial statements as of June 30, 2026 and for the three and six months ended June 30, 2026 and 2025, have been prepared by the Company, pursuant to the rules and regulations of the SEC for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2025 and notes thereto, included in the Company’s final prospectus for the IPO filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of June 30, 2026 and condensed consolidated results of operations, condensed consolidated statements of redeemable convertible preferred stock and stockholders’ deficit for the three and six months ended June 30, 2026 and 2025 and condensed consolidated cash flows for the six months ended June 30, 2026 and 2025 have been made. The results of operations for the three and six months ended June 30, 2026 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2026. Other than the policies noted below, there have been no changes from the significant accounting policies and estimates disclosed in Note 2 to the Company’s audited consolidated financial statements for the year ended December 31, 2025 included in the Company’s final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include the fair value of marketable securities, the fair values of preferred stock tranche liabilities, the fair value of common stock, valuation of deferred tax assets, incremental borrowing rate for leases, accruals for research and development activities and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
Segments	Segments Operating segments are defined as components of an entity for which separate financial information is available and regularly utilized by the Chief Operating Decision Maker (“CODM”) to assess the Company’s performance for capital and resource allocation decisions. The Company’s CODM is its Chief Executive Officer, who reviews such financial information on an aggregate company-level basis (see Note 14). The Company has determined it operates as a single operating segment and has one reportable segment, which is the research and development of therapeutic products in the fields of immune-mediated diseases. Revenue is generated exclusively from transactions with a party located in the United States of America. All long-lived assets are maintained in the United States.
Concentration of Credit Risk and of Significant Suppliers	Concentration of Credit Risk and of Significant Suppliers Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and restricted cash. The Company is exposed to credit risk from its deposits of cash and cash equivalents in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company has not experienced any losses on its deposits of cash and cash equivalents during the periods presented. The Company invests in money market funds, U.S. Treasury bills and notes, and other short-term fixed income securities which can be subject to certain credit risks. The Company mitigates these risks by investing in high-grade instruments, limiting its exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its financial instruments. The Company is dependent on third-party manufacturers to supply materials for research and development activities for the Company’s pipeline products, including preclinical and clinical studies and testing, and manufacturing activities. In particular, the Company relies on a small number of manufacturers for the supply of drug substance and drug product materials for its clinical assets. The Company’s preclinical and clinical studies and testing and manufacturing activities could be adversely affected by a significant interruption in the supply of materials from its suppliers.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance and reporting. The Company’s product candidates are still in either preclinical or clinical development and, to date, none of the Company’s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs, consisting of legal, accounting and other third-party fees directly relating to in-process equity financings or offerings are capitalized. The deferred offering costs will be offset against offering proceeds upon the completion of the financing or the offering. As of June 30, 2026 and December 31, 2025, deferred offering costs of $2.5 million and $1.2 million, respectively, were capitalized and recorded as non-current assets on the condensed consolidated balance sheets. Upon closing the IPO in August 2026, all deferred offering costs were charged against the proceeds from the IPO and recorded in stockholders’ deficit as a reduction of additional paid-in capital.
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Net loss attributable to common stockholders is computed as net loss less accretion of redeemable convertible preferred stock. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, unvested restricted stock awards and stock options are considered to be potentially dilutive securities. Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock and unvested restricted stock awards are considered participating securities. The redeemable convertible preferred stock does not have a contractual obligation to share in the Company’s losses, and unvested restricted stock awards are considered contingently issuable shares for accounting purposes. Because the Company has reported a net loss for the periods presented, the diluted net loss per share of common stock is the same as basic net loss per common share for the periods presented.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) under its Accounting Standards Codification (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”) and adopts new or revised accounting standards on the dates applicable to nonpublic entities unless it adopts such standards early. Accounting Pronouncements Not Yet Adopted In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220), requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual periods beginning after December 15, 2027. The requirements of ASU 2024-03 may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting ASU 2024-03 on its condensed consolidated financial statements and disclosures.

Share-based Compensation (Tables)

6 Months Ended

Jun. 30, 2026

Share-Based Payment Arrangement [Abstract]

Summary of Stock Option Activity

A summary of stock option activity is set forth below:


	Outstanding Awards
	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding, January 1, 2026		2,642,930		$	3.93		8.76	$	2,621
Granted		80,817		$	7.99
Exercised		(21,992	)	$	1.92			$	134
Forfeited or expired		(15,675	)	$	4.58
Outstanding, June 30, 2026		2,686,080		$	4.07		8.31	$	14,031
Shares exercisable, June 30, 2026		1,102,348		$	3.72		8.11	$	6,144
Vested and expected to vest, June 30, 2026		2,686,080		$	4.07		8.31	$	14,031

Summary of Restricted Stock Awards

Activity with respect to restricted stock awards was as follows:


	Restricted Stock Awards			Weighted Average Grant Date Fair Value
Unvested at January 1, 2026		333,678		$	2.69
Vested		(125,136	)	$	2.69
Unvested at June 30, 2026		208,542		$	2.69

Summary of Stock-based Compensation Expense

The following table presents the classification of stock-based compensation expense related to awards granted to employees and non-employees (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Research and development	$	241	$	184	$	480	$	338
General and administrative		451		379		898		687
Total stock-based compensation expense	$	692	$	563	$	1,378	$	1,025

License Agreements (Additional Information) (Details) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 31, 2025	Jun. 01, 2023	Sep. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
License Agreements
Common Stock Issued				4,529,100		4,529,100		4,507,108
Contract liability				$ 0		$ 0		$ 450
Alamar Platform License Agreement [Member] \| Alamar Biosciences, Inc [Member]
License Agreements
Common Stock Issued		2,428,646
Milestone payments				0	$ 0	$ 0	$ 0
Alamar Platform License Agreement [Member] \| Maximum \| Alamar Biosciences, Inc [Member]
License Agreements
Development milestone payments		$ 800
Regulatory milestone payments		3,500
Milestone payments		$ 4,300
EndPath RadioTherapeutics, Inc. [Member]
License Agreements
Development and regulatory milestone payments	$ 14,500
Common stock received as noncash consideration subject to repurchase	6,000,000					6,000,000		6,000,000
Customer deposit liability				600		$ 600		$ 600
Common stock received as noncash consideration	24,000,000
EndPath RadioTherapeutics, Inc. [Member] \| Royalty [Member]
License Agreements
Sales milestone payments	$ 170,000
EndPath License Agreement [Member]
License Agreements
Contract liability				0		0		$ 500
Common stock distributed as noncash consideration			24,000,000
Aggregate carrying value of noncash consideration received			$ 2,400
Recognizes revenue				$ 500	$ 0	$ 500	$ 0

Summary of Significant Accounting Policies (Additional Information) (Details) $ in Millions		6 Months Ended
	Jul. 22, 2026	Jun. 30, 2026 USD ($) Segment	Dec. 31, 2025 USD ($)
Summary of Significant Accounting Policies [Line Items]
Deferred Offering Costs \| $		$ 2.5	$ 1.2
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]		srt:ChiefExecutiveOfficerMember
Number of operating segment		1
Number of reportable segments		1
Subsequent Event
Summary of Significant Accounting Policies [Line Items]
Reverse stock split ratio	1-for-9.29

Balance Sheet Components - Schedule Of Property and Equipment Net Consists (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Property, Plant, and Equipment [Line Items]
Property, Plant, and Equipment Gross	$ 4,928	$ 4,589
Less: Accumulated depreciation	(1,585)	(1,097)
Property and equipment, net	$ 3,343	3,492
Laboratory equipment
Property, Plant, and Equipment [Line Items]
Estimated Useful Life	5 years
Property, Plant, and Equipment Gross	$ 4,210	3,907
Computer equipment and software
Property, Plant, and Equipment [Line Items]
Estimated Useful Life	3 years
Property, Plant, and Equipment Gross	$ 245	245
Furniture and fixtures
Property, Plant, and Equipment [Line Items]
Estimated Useful Life	7 years
Property, Plant, and Equipment Gross	$ 273	273
Leasehold improvements
Property, Plant, and Equipment [Line Items]
Estimated Useful Life	15 years
Property, Plant, and Equipment Gross	$ 136	136
Construction in progress
Property, Plant, and Equipment [Line Items]
Property, Plant, and Equipment Gross	$ 64	$ 28

Fair Value Measurements - Summary of Changes in the Fair Value (Details) - Level 3 [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2025 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value as of December 31, 2024	$ 6,638
Change in the fair value of Series B preferred stock tranche liability	170
Fair value upon settlement	(6,808)
Fair value as of June 30, 2025	$ 0

Fair Value Measurements - Schedule of Fair Value of the Company's Financial Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025	Jun. 30, 2025
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 32,829	$ 40,193	$ 42,645
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	114,765	150,086
Fair Value, Recurring [Member] \| U.S. Treasury Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	73,411	82,397
Fair Value, Recurring [Member] \| U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		2,485
Marketable securities	8,892	29,678
Money Market Funds [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	32,462	35,526
Level 1 [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	114,765	132,659
Level 1 [Member] \| Fair Value, Recurring [Member] \| U.S. Treasury Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	73,411	82,397
Level 1 [Member] \| Fair Value, Recurring [Member] \| U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		0
Marketable securities	8,892	14,736
Level 1 [Member] \| Money Market Funds [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	32,462	35,526
Level 2 [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	0	17,427
Level 2 [Member] \| Fair Value, Recurring [Member] \| U.S. Treasury Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Level 2 [Member] \| Fair Value, Recurring [Member] \| U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		2,485
Marketable securities	0	14,942
Level 2 [Member] \| Money Market Funds [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Level 3 [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	0	0
Level 3 [Member] \| Fair Value, Recurring [Member] \| U.S. Treasury Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	0	0
Level 3 [Member] \| Fair Value, Recurring [Member] \| U.S. Treasury Bills [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		0
Marketable securities	0	0
Level 3 [Member] \| Money Market Funds [Member] \| Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 0	$ 0

Organization and Nature of the Business

6 Months Ended

Jun. 30, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Nature of the Business

Attovia Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company headquartered in San Carlos, California and focused on research and development of therapeutic products in the fields of immune-mediated diseases. The Company was incorporated in the State of Delaware on December 16, 2022 and subsequently commenced principal operations in June 2023.

As of June 30, 2026, the Company had two wholly owned subsidiaries, Attovia Therapeutics Cayman Co., Ltd., an exempted company incorporated in the Cayman Islands with limited liability in July 2025, and Attovia Therapeutics (Shanghai) Co., Ltd., a limited liability company incorporated in the People’s Republic of China in October 2025.

Initial Public Offering

On August 4, 2026, the Company’s registration statement on Form S-1 (File No. 333-297452) relating to its initial public offering (the “IPO”) of common stock became effective. The IPO closed on August 6, 2026, at which time the Company issued 19,550,000 shares of its common stock at a price of $17.00 per share, which included the issuance of shares in connection with the exercise by the underwriters of their option to purchase up to 2,550,000 additional shares. The Company received an aggregate of $332.4 million in gross proceeds, before underwriting discounts and commissions and offering costs.

Upon the closing of the IPO, all outstanding shares of the Company’s redeemable convertible preferred stock converted into 21,517,976 shares of common stock. In connection with the completion of the IPO, on August 6, 2026, the Company’s then-current restated certificate of incorporation, as amended, was amended and restated to provide for 500,000,000 authorized shares of common stock, par value of $0.0001 per share, and 10,000,000 authorized shares of preferred stock, par value of $0.0001 per share. The unaudited interim condensed consolidated financial statements as of June 30, 2026, including share and per share amounts, do not give effect to the IPO, as it closed subsequent to June 30, 2026.

Liquidity

The Company has incurred significant net operating losses and negative cash flows from operations since inception and had an accumulated deficit of $150.4 million as of June 30, 2026. The Company has historically financed its operations primarily through the private placements of equity securities. On August 6, 2026, the Company completed the IPO and received approximately $305.4 million in net proceeds after deducting underwriting discounts and commissions and estimated offering costs.

As of June 30, 2026, the Company had cash, cash equivalents and marketable securities of $115.1 million. The Company will continue to require substantial additional capital in the future to support further development of its product candidates and maintain its operations. Until such time as it can generate significant revenue from product sales, if ever, the Company expects to raise additional capital through equity or debt financings, collaborations, licensing arrangements or other sources. Management believes that the Company’s existing cash, cash equivalents and marketable securities, together with the net proceeds from the IPO, will be sufficient to fund the Company’s planned operations for at least 12 months from the date of the issuance of these condensed consolidated financial statements.

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2026

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Commitments under the Operating Lease

As of June 30, 2026, the future minimum lease commitments under the operating lease were as follows (in thousands):


(in thousands)
Year ended December 31,
2026 (remainder of the year)	$	1,134
2027		2,333
2028		1,200
Total future minimum lease payments	$	4,667
Less: Imputed interest		(341	)
Present value of operating lease liabilities	$	4,326

Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Balance Sheet Related Disclosures [Abstract]
Accrued compensation	$ 1,905	$ 3,103
Accrued research and development expenses	2,549	1,069
Accrued professional fees	29	556
Contract liability	0	450
Other accrued expenses and current liabilities	92	357
Total accrued expenses and other current liabilities	$ 4,575	$ 5,535

Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2026	Dec. 31, 2025	Mar. 31, 2025	May 31, 2024
Class of Stock [Line Items]
Shares Authorized	199,902,270	199,902,270
Shares Issued	199,902,270	199,902,270
Shares Outstanding		199,902,270
Carrying Value	$ 258,226	$ 258,226
Temporary Equity, Liquidation Preference	$ 255,850	$ 255,850
Series A-1
Class of Stock [Line Items]
Shares Authorized	30,425,000	30,425,000
Original Isuue Price	$ 1	$ 1
Shares Issued	30,425,000	30,425,000
Shares Outstanding	30,425,000	30,425,000
Carrying Value	$ 26,046	$ 26,046
Temporary Equity, Liquidation Preference	$ 30,425	$ 30,425
Series A-2
Class of Stock [Line Items]
Shares Authorized	27,659,090	27,659,090
Original Isuue Price	$ 1.1	$ 1.1
Shares Issued	27,659,090	27,659,090
Shares Outstanding	27,659,090	27,659,090
Carrying Value	$ 30,407	$ 30,407
Temporary Equity, Liquidation Preference	$ 30,425	$ 30,425
Series B
Class of Stock [Line Items]
Shares Authorized	76,363,636	76,363,636
Original Isuue Price	$ 1.38	$ 1.38		$ 1.375
Shares Issued	76,363,636	76,363,636		38,181,818
Shares Outstanding	76,363,636	76,363,636
Carrying Value	$ 111,773	$ 111,773		$ 47,500
Temporary Equity, Liquidation Preference	$ 105,000	$ 105,000
Series C
Class of Stock [Line Items]
Shares Authorized	65,454,544	65,454,544
Original Isuue Price	$ 1.38	$ 1.38	$ 1.375
Shares Issued	65,454,544	65,454,544	65,454,544
Shares Outstanding	65,454,544	65,454,544
Carrying Value	$ 90,000	$ 90,000
Temporary Equity, Liquidation Preference	$ 90,000	$ 90,000

Common Stock (Tables)

6 Months Ended

Jun. 30, 2026

Stockholders' Equity Note [Abstract]

Schedule of common stock shares reserved for future issuance

The Company had reserved common stock, on an as-converted basis, for future issuance as follows:


	June 30, 2026		December 31, 2025
Conversion of redeemable convertible preferred shares		21,517,976		21,517,976
Stock options issued and outstanding		2,686,080		2,642,930
Stock options available for future grant		383,816		448,980
Total common stock reserved		24,587,872		24,609,886

Subsequent Events

6 Months Ended

Jun. 30, 2026

Subsequent Events [Abstract]

Subsequent Events

15.

Subsequent Events

On July 22, 2026, in addition to approving the Reverse Stock Split described in Note 2, the board of directors approved grants of stock options upon the effectiveness of the Company’s registration statement on Form S-1 (File No. 333-297452) relating to the IPO covering an aggregate of 1,642,700 shares of common stock to certain employees, consultants, and members of the board of directors. The awards are subject to service-based vesting requirements. The exercise price of the options equals the initial public offering price of $17.00 per share.

In July 2026, prior to the IPO closing, the Company’s board of directors and stockholders approved the 2026 Equity Incentive Plan (the “2026 Plan”), which became effective on August 3, 2026. The Company initially reserved 4,900,000 shares of common stock for issuance of share-based compensation awards, plus any reserved shares not issued or subject to outstanding grants under the 2023 Plan on the effective date of the 2026 Plan. Awards granted under the 2026 Plan may be either incentive stock options (“ISOs”), nonqualified stock options (“NSOs”), restricted stock units, RSAs, stock appreciation rights and other stock-based awards. Shares of common stock subject to awards granted under the 2023 Plan that are forfeited or lapse unexercised will be available for issuance under the 2026 Plan. Once the 2026 Plan became effective, no further grants were made under the 2023 Plan.

In July 2026, the Company’s board of directors and stockholders approved the 2026 Employee Stock Purchase Plan (“ESPP”), which became effective on August 4, 2026. The ESPP allows eligible employees to purchase shares of the Company’s common stock through payroll deductions at a purchase price equal to 85% of the lesser of the fair market value of the common stock on (i) the first trading day of the applicable offering period or (ii) the last trading day of the applicable purchase period. Each offering period may itself consist of one or more purchase periods. No offering period may be longer than 27 months. There were 410,000 shares of common stock initially reserved for issuance under the ESPP. The number of common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2027 through January 1, 2036, by the lesser of (a) 1% of the total number of shares of all classes of the Company’s common stock, plus the total number of shares of the Company’s common stock issuable upon conversion of any preferred stock (if any) and the total number of shares of the Company’s common stock subject to any pre-funded warrants, as issued and outstanding as of the immediately preceding December 31; and (b) such number of shares of common stock determined by the board of directors of the Company or compensation committee.

Balance Sheet Components - Schedule of Marketable Securities Classified as Available-for-Sale (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Marketable Securities [Line Items]
Amortized Cost	$ 82,389	$ 111,976
Unrealized Gain	1	100
Unrealized Loss	(87)	(1)
Estimated Fair Value	82,303	112,075
U.S. Treasury notes
Marketable Securities [Line Items]
Amortized Cost	73,493	82,309
Unrealized Gain	1	89
Unrealized Loss	(83)	(1)
Estimated Fair Value	73,411	82,397
U.S. Treasury bills
Marketable Securities [Line Items]
Amortized Cost	8,896	29,667
Unrealized Gain	0	11
Unrealized Loss	(4)	0
Estimated Fair Value	$ 8,892	$ 29,678

Share-based Compensation (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Class of Stock [Line Items]
Total fair value of options vested	$ 1.5	$ 0.9
Weighted-average grant date fair value of options granted	$ 5.17	$ 3.28
Employee Stock Option Member
Class of Stock [Line Items]
Unrecognized stock-based compensation expense	$ 4.8
unrecognized stock-based compensation expense, period for recognition	2 years 3 months 18 days
Restricted Stock [Member]
Class of Stock [Line Items]
Unrecognized stock-based compensation expense	$ 0.6
unrecognized stock-based compensation expense, period for recognition	9 months 18 days
2023 Plan
Class of Stock [Line Items]
Shares of common stock authorized and reserved for issuance	3,293,424
Shares available for future grant	383,816

Preferred Stock Tranche Liability

6 Months Ended

Jun. 30, 2026

Equity [Abstract]

Preferred Stock Tranche Liability

The Company determined that the contingent obligation to issue additional shares of Series B redeemable convertible preferred stock (the “Series B Second Tranche Shares”) upon the achievement of a specified development milestone (the “Series B Milestone”), at the related closing (the “Series B Milestone Closing”), represented a freestanding instrument. This instrument, referred to as the Series B preferred stock tranche liability, was accounted for as a liability, initially recorded and subsequently remeasured at fair value until the settlement or expiration.

The Series B preferred stock tranche was settled in January 2025 when the Series B milestone was achieved. The Company remeasured the Series B preferred stock tranche liability in January 2025 and determined that the fair value of the liability was $6.8 million, and recorded an approximately $0.2 million loss in its condensed consolidated statements of operations and comprehensive loss during the six months ended June 30, 2025.

The preferred stock tranche liability was valued using a probability-weighted present value calculation. In determining the fair value of the preferred stock tranche liability, estimates and assumptions impacting fair value included (i) discount rates, (ii) the expected term of the forward, and (iii) the probability of the tranche closing. Significant increases (decreases) in any of those inputs in isolation may result in a significant change in fair value measurement. The Company determined the per share future value of the Series B redeemable convertible preferred stock by back-solving to the original issue price of the Series B redeemable convertible preferred stock financing. In January 2025, upon the achievement of the Series B milestone, the Series B Milestone Closing was completed, and the associated Series B preferred stock tranche liability was settled. The fair value of the Series B redeemable convertible preferred stock was $1.55 per share and represented the only input used in determining the fair value of the Series B preferred stock tranche liability upon the Series B Milestone Closing.

Commitments and Contingencies - Schedule of Future Minimum Lease Commitments under the Operating Lease (Details) $ in Thousands	Jun. 30, 2026 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2026 (remainder of the year)	$ 1,134
2027	2,333
2028	1,200
Total future minimum lease payments	4,667
Less: Imputed interest	(341)
Present value of operating lease liabilities	$ 4,326

Related Party Transactions - Additional Information (Details) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	Mar. 31, 2025	Jun. 30, 2023 ft² shares	Jun. 30, 2026 USD ($) shares	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) shares	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($) shares
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Common Stock Issued \| shares			4,529,100		4,529,100		4,507,108
Company Owned Shares \| shares			4,529,100		4,529,100		4,507,108
Expense Recognized					$ 795	$ 632
Alamar
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Common Stock Issued \| shares		2,428,646
Company Owned Shares \| shares		800,632
Services agreement expense			$ 200		200	100
Alamar \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Services agreement expense				$ 100
Alamar Lease Agreement \| Alamar
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Lease Area \| ft²		10,422
Lease Expiration	Mar. 31, 2025
Lease Description		the Company entered into a lease agreement with Alamar, which was amended four times between October 2023 and October 2024
Expense Recognized				$ 0		$ 200
Services Agreement \| Alamar \| Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accounts Payable			$ 100		$ 100		$ 100

Segment Reporting - Schedule of disaggregated amounts that comprised research and development expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
External costs
Clinical, manufacturing, and preclinical services	$ 13,971	$ 9,206	$ 25,866	$ 17,216
Professional consulting services	889	666	1,507	1,194
Consumables and other research and development costs	728	844	1,480	1,397
Internal costs
Personnel-related costs	2,923	2,561	5,940	5,073
Facilities and overhead costs	435	311	899	564
Total research and development expenses	$ 18,946	$ 13,588	$ 35,692	$ 25,444

Share-based Compensation - Summary of Restricted Stock Awards (Details) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2026 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested at January 1, 2026, Shares \| shares	333,678
Vested, Shares \| shares	(125,136)
Unvested at June 30, 2026, Shares \| shares	208,542
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested at January 1, 2026, Shares \| $ / shares	$ 2.69
Vested, Shares \| $ / shares	2.69
Unvested at June 30, 2026, Shares \| $ / shares	$ 2.69

Redeemable Convertible Preferred Stock

6 Months Ended

Jun. 30, 2026

Equity [Abstract]

Redeemable Convertible Preferred Stock

As of June 30, 2026 and December 31, 2025, redeemable convertible preferred stock consisted of the following (in thousands, except share and price data):


	June 30, 2026 and December 31, 2025
	Shares Authorized		Original Issue Price		Shares Issued and Outstanding		Carrying Value		Liquidation Value
Series A-1		30,425,000	$	1.00		30,425,000	$	26,046	$	30,425
Series A-2		27,659,090	$	1.10		27,659,090		30,407		30,425
Series B		76,363,636	$	1.38		76,363,636		111,773		105,000
Series C		65,454,544	$	1.38		65,454,544		90,000		90,000
		199,902,270				199,902,270	$	258,226	$	255,850

In May 2024, the Company entered into the Series B redeemable convertible preferred stock purchase agreement (the “Series B Purchase Agreement”) with certain investors and issued 38,181,818 shares of Series B redeemable convertible preferred stock at

$1.375 per share for total gross proceeds of $52.5 million. The Series B Purchase Agreement also provided for the issuance and sale to the same investors of an additional 38,181,818 shares of Series B redeemable convertible preferred stock (“Series B Second Tranche Shares”) on the same terms as the shares issued at the initial closing, upon achieving the first dosing milestone or if the achievement of such milestone conditions is waived in writing by the holders of at least 66% of the then-outstanding shares of Series B redeemable convertible preferred stock (the “Series B Requisite Holders”) and the Board of Directors of the Company, including a majority of the then seated Preferred Directors (the “Series B Milestone Closing”) on or before June 30, 2026, or, at the option of the investors, at any time before that date. The Series B redeemable convertible preferred stock was recorded at its fair value of $47.5 million, less issuance costs of $0.3 million.

In January 2025, upon the achievement of the Series B milestone, the remaining 38,181,818 shares of the Series B redeemable convertible preferred stock were issued at a price of $1.375 per share, which resulted in gross cash proceeds of $52.5 million. As a result of this issuance, the Series B preferred stock tranche liability of $6.8 million was settled and the Series B redeemable convertible preferred stock was recorded at its fair value of $59.3 million, less issuance costs of less than $0.1 million (see Note 8).

In March 2025, the Company issued 65,454,544 shares of its Series C redeemable convertible preferred stock at a purchase price of $1.375 per share for total gross proceeds of $90.0 million. The Series C redeemable convertible preferred stock was recorded at fair value based on proceeds received, less issuance costs of $0.3 million.

On August 6, 2026, upon the closing of the Company’s IPO, all outstanding redeemable convertible preferred stock automatically converted into 21,517,976 shares of common stock. Prior to the closing of the Company’s IPO, the holders of redeemable convertible preferred stock had the following rights and preferences:

Liquidation Preference

In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary or a deemed liquidation event, including a merger, acquisition or sale of all or substantially all of the Company’s assets, (each a “Liquidation Event”), the holders of Series C and Series B redeemable convertible preferred stock were entitled to receive on a pari passu basis, prior and in preference to any distribution of any of the assets of the Company to the holders of Series A-1 redeemable convertible preferred stock, Series A-2 redeemable convertible preferred stock and common stock, an amount per share equal to the original issue price, plus any dividends declared but unpaid thereon.

After full payment to holders of the Series C and Series B redeemable convertible preferred stock, the holders of Series A-1 and A-2 redeemable convertible preferred stock were entitled to receive on a pari passu basis, prior and in preference to any distribution of any of the assets of the Company to the holders of common stock, an amount per share equal to the applicable original issue price, plus any dividends declared but unpaid thereon.

If the assets and funds were insufficient to permit the payment to holders of the redeemable convertible preferred stock of the full preferential amounts, then the entire assets and funds legally available for distribution to stockholders would be distributed ratably among the holders of the respective series of redeemable convertible preferred stock in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

Upon completion of the distributions of the full amounts required above, all of the remaining assets of the Company available for distribution would be distributed among the holders of redeemable convertible preferred stock and common stock pro rata on an as-converted basis, provided, however, that if the aggregate amount the holders of redeemable convertible preferred stock were entitled to receive exceeded two and one-half times the applicable original issue price per share of the redeemable convertible preferred stock, as adjusted, plus any dividends declared but unpaid thereon (the “Participation Cap”), each holder of the redeemable convertible preferred stock would only be entitled to receive the greater of (a) the Participation Cap and (b) the amount such holder would have received if all shares of such series of redeemable convertible preferred stock had been converted into common stock immediately prior to such Liquidation Event.

Conversion

Each share of redeemable convertible preferred stock was convertible, at the option of the holder thereof, at any time, into such number of fully paid and nonassessable shares of common stock as was determined by dividing the applicable original issue price by the conversion price of $9.29 for shares of Series A-1 redeemable convertible preferred stock, $10.22 for Series A-2 redeemable convertible preferred stock and $12.77 for shares of Series B and Series C redeemable convertible preferred stock, as adjusted for any stock splits, stock dividends, combinations, recapitalizations or the like, as well as any down-round anti-dilution adjustments.

Each share of redeemable convertible preferred stock would automatically be converted into shares of common stock at the then-effective conversion rate either (a) upon the closing of the sale of shares of common stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, that was

either (i) approved by the holders of at least 66% of the outstanding shares of redeemable convertible preferred stock, voting together as a single class on an as-converted basis (“Requisite Holders”), including the Series B Requisite Holders and Series C Requisite Holders, or (ii) at a price of at least $15.33 per share, resulting in at least $100.0 million of gross proceeds to the Company and in connection with such offering the Company’s common stock was listed for trading on the Nasdaq Stock Market’s National Market, the New York Stock Exchange or such other international exchange of equal stature, or (b) by vote or written consent of the Requisite Holders.

Dividends

The holders of the outstanding shares of Series C and Series B redeemable convertible preferred stock were entitled to receive, only when, as and if declared by the Company’s board of directors, out of any funds and assets legally available therefor, non-cumulative dividends at the rate of 8% of the original issue price for each share of Series C and Series B redeemable convertible preferred stock, prior and in preference to any dividends paid to the holders of Series A-1 redeemable convertible preferred stock, Series A-2 redeemable convertible preferred stock and common stock (other than dividends on shares of common stock payable in shares of common stock). The holders of the outstanding shares of Series A-2 and Series A-1 redeemable convertible preferred stock were entitled to receive, only when, as and if declared by the Company’s board of directors, out of any funds and assets legally available therefor, non-cumulative dividends at the rate of 8% of the original issue price for each share of Series A-1 and Series A-2 redeemable convertible preferred stock, prior and in preference to any dividends paid to the holders of common stock (other than dividends on shares of common stock payable in shares of common stock). After payment of the full amount of any dividends described above, any additional dividends would be distributed among all holders of common stock and the redeemable convertible preferred stock on an as-converted basis. Whenever a dividend was payable in property other than cash, the value of such dividend was deemed to be the fair market value of such property as determined in good faith by the Company’s board of directors.

No dividends were declared as of June 30, 2026 and December 31, 2025.

Voting

The holders of each share of redeemable convertible preferred stock were entitled to the number of votes equal to the number of shares of common stock into which such shares of redeemable convertible preferred stock could be converted. With respect to such votes, the holders had full voting rights and powers equal to the voting rights and powers of common stock.

The holders of Series C redeemable convertible preferred stock, exclusively and as a separate class, were entitled to elect one director of the Company. The holders of Series B redeemable convertible preferred stock, exclusively and as a separate class, were entitled to elect one director of the Company. The holders of Series A-1 redeemable convertible preferred stock and Series A-2 redeemable convertible preferred stock, exclusively and as a separate class, were entitled to elect two directors of the Company. The holders of common stock, exclusively and as a separate class, were entitled to elect two directors of the Company. The holders of shares of redeemable convertible preferred stock and common stock were entitled, voting together as a combined class and on an as-converted basis, to elect the remaining directors of the Company.

Redemption

The shares of Series C redeemable convertible preferred stock were to be redeemed by the Company at a price per share equal to the applicable original issue price, plus all declared but unpaid dividends thereon, in one installment commencing not more than 60 days after receipt by the Company and the other holders of Series C redeemable convertible preferred stock of written notice requesting redemption of all shares of Series C redeemable convertible preferred stock held by such holder of Series C redeemable convertible preferred stock. Such redemption could occur at any time on or after March 31, 2035, provided that a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, or a deemed liquidation event, had not occurred prior to that date.

The shares of Series B redeemable convertible preferred stock were to be redeemed by the Company at a price per share equal to the applicable original issue price, plus all declared but unpaid dividends thereon, in one installment commencing not more than 60 days after receipt by the Company and the other holders of Series B redeemable convertible preferred stock of written notice requesting redemption of all shares of Series B redeemable convertible preferred stock held by such holder of Series B redeemable convertible preferred stock. Such redemption could occur at any time on or after March 31, 2035, provided that a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, or a deemed liquidation event, had not occurred prior to that date.

The shares of Series A-1 redeemable convertible preferred stock and Series A-2 redeemable convertible preferred stock were not redeemable other than upon the occurrence of a Liquidation Event.

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2026	Aug. 31, 2026
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2026
Document Fiscal Year Focus	2026
Entity File Number	001-43423
Entity Registrant Name	Attovia Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	92-1510574
Entity Address, Address Line One	1091 Industrial Road,
Entity Address, Address Line Two	Suite 310
Entity Address, City or Town	San Carlos
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94070
City Area Code	510
Local Phone Number	399-5001
Title of 12(b) Security	Common stock, $0.0001 par value per share
Trading Symbol	ATTO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		45,651,262
Entity Central Index Key	0002058707
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Amendment Flag	false

Common Stock - Schedule of Common Shares Reserved for Issuance (Details) - shares	Jun. 30, 2026	Dec. 31, 2025
Class of Stock [Line Items]
Total common stock reserved	24,587,872	24,609,886
Redeemable Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Total common stock reserved	21,517,976	21,517,976
Stock Options Issued and Outstanding [Member]
Class of Stock [Line Items]
Total common stock reserved	2,686,080	2,642,930
Shares Available for Future Option Grants Equity [Member]
Class of Stock [Line Items]
Total common stock reserved	383,816	448,980

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Share-based Compensation

6 Months Ended

Jun. 30, 2026

Share-Based Payment Arrangement [Abstract]

Share-based Compensation

10.

Share-based Compensation

In 2023, the Company adopted the 2023 Equity Incentive Plan (“2023 Plan”), under which the Board of Directors can issue options to purchase shares of common stock. As of June 30, 2026, there were 3,293,424 shares of common stock authorized and reserved for issuance under the 2023 Plan, of which 383,816 shares remained available for future grant.

Options

A summary of stock option activity is set forth below:


	Outstanding Awards
	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Outstanding, January 1, 2026		2,642,930		$	3.93		8.76	$	2,621
Granted		80,817		$	7.99
Exercised		(21,992	)	$	1.92			$	134
Forfeited or expired		(15,675	)	$	4.58
Outstanding, June 30, 2026		2,686,080		$	4.07		8.31	$	14,031
Shares exercisable, June 30, 2026		1,102,348		$	3.72		8.11	$	6,144
Vested and expected to vest, June 30, 2026		2,686,080		$	4.07		8.31	$	14,031

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock as of June 30, 2026.

The total fair value of options that vested during the six months ended June 30, 2026 and 2025 was $1.5 million and $0.9 million, respectively. The weighted-average grant date fair value of options granted during the six months ended June 30, 2026 and 2025 was $5.17 and $3.28, respectively.

As of June 30, 2026, there was $4.8 million of unrecognized stock-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.3 years.

Restricted Stock Awards (“RSAs”)

Activity with respect to restricted stock awards was as follows:


	Restricted Stock Awards			Weighted Average Grant Date Fair Value
Unvested at January 1, 2026		333,678		$	2.69
Vested		(125,136	)	$	2.69
Unvested at June 30, 2026		208,542		$	2.69

As of June 30, 2026, there was $0.6 million of unrecognized stock-based compensation expense related to unvested RSAs, which is expected to be recognized over a weighted-average period of 0.8 years. No RSAs were repurchased or cancelled during the six months ended June 30, 2026 and 2025.

Stock-Based Compensation Expense

The following table presents the classification of stock-based compensation expense related to awards granted to employees and non-employees (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Research and development	$	241	$	184	$	480	$	338
General and administrative		451		379		898		687
Total stock-based compensation expense	$	692	$	563	$	1,378	$	1,025

Share-based Compensation - Summary of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2026 USD ($) $ / shares shares	Dec. 31, 2025 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, January 1, 2026 \| shares	2,642,930
Granted \| shares	80,817
Exercised \| shares	(21,992)
Forfeited or expired \| shares	(15,675)
Outstanding, June 30, 2026 \| shares	2,686,080	2,642,930
Shares exercisable, June 30, 2026 \| shares	1,102,348
Vested and expected to vest, June 30, 2026 \| shares	2,686,080
Outstanding, January 1, 2026 \| $ / shares	$ 3.93
Granted \| $ / shares	7.99
Exercised \| $ / shares	1.92
Forfeited or expired \| $ / shares	4.58
Outstanding, June 30, 2026 \| $ / shares	4.07	$ 3.93
Shares exercisable, June 30, 2026 \| $ / shares	3.72
Vested and expected to vest, June 30, 2026 \| $ / shares	$ 4.07
Outstanding, January 1, 2026	8 years 3 months 21 days	8 years 9 months 3 days
Shares exercisable, June 30, 2026	8 years 1 month 9 days
Vested and expected to vest, June 30, 2026	8 years 3 months 21 days
Outstanding, January 1, 2026 \| $	$ 2,621
Exercised \| $	134
Outstanding, June 30, 2026 \| $	14,031	$ 2,621
Shares exercisable, June 30, 2026 \| $	6,144
Vested and expected to vest, June 30, 2026 \| $	$ 14,031

Segment Reporting

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Segment Reporting

14.

Segment Reporting

The CODM uses net loss to measure segment loss and assesses performance against expectations to make resource allocation decisions. In making this assessment, the CODM reviews and evaluates net loss to monitor budget versus actual results and to analyze cash flows for purposes of allocating resources and assessing financial performance. Additionally, the CODM reviews and uses significant expense categories included within net loss as well as the disaggregated amounts within research and development expenses indicated in the table below to manage the Company’s operations. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.

In addition to the significant expense categories included within net loss presented on the Company’s condensed consolidated statements of operations and comprehensive loss, the following table provides disaggregated amounts that comprised research and development expenses (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
External costs
Clinical, manufacturing, and preclinical services	$	13,971	$	9,206	$	25,866	$	17,216
Professional consulting services		889		666		1,507		1,194
Consumables and other research and development costs		728		844		1,480		1,397
Internal costs
Personnel-related costs		2,923		2,561		5,940		5,073
Facilities and overhead costs		435		311		899		564
Total research and development expenses	$	18,946	$	13,588	$	35,692	$	25,444

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details

Balance Sheet Components (Additional Information) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Balance Sheet Related Disclosures [Abstract]
Accrued interest receivable	$ 900,000		$ 900,000		$ 900,000
Depreciation and amortization expense	200,000	$ 200,000	500,000	$ 400,000
Impairment losses on investments	$ 0	$ 0	$ 0	$ 0

Redeemable Convertible Preferred Stock (Additional Information) (Details) - USD ($)	1 Months Ended			6 Months Ended
	Mar. 31, 2025	Jan. 31, 2025	May 31, 2024	Jun. 30, 2026	Jun. 30, 2025	Aug. 06, 2026	Dec. 31, 2025
Class of Stock [Line Items]
Redeemable convertible preferred stock				199,902,270			199,902,270
Redeemable convertible preferred stock				$ 258,226,000			$ 258,226,000
Issuance Cost				$ 1,839,000	$ 371,000
Redeemable Convertible Preferred Stock Voting Percent				66.00%
Dividends declared				$ 0			$ 0
Non Cumulative Dividends Rate				8.00%
Subsequent Event
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion						21,517,976
Minimum [Member]
Class of Stock [Line Items]
Temporary equity minimum proceeds from offering for conversion				$ 100,000,000
Series A-1
Class of Stock [Line Items]
Redeemable convertible preferred stock				30,425,000			30,425,000
Redeemable convertible preferred stock price per share				$ 1			$ 1
Redeemable convertible preferred stock				$ 26,046,000			$ 26,046,000
Preferred Stock, Convertible, Conversion Price				$ 9.29
Series A-2
Class of Stock [Line Items]
Redeemable convertible preferred stock				27,659,090			27,659,090
Redeemable convertible preferred stock price per share				$ 1.1			$ 1.1
Redeemable convertible preferred stock				$ 30,407,000			$ 30,407,000
Preferred Stock, Convertible, Conversion Price				$ 10.22
Series B
Class of Stock [Line Items]
Redeemable convertible preferred stock			38,181,818	76,363,636			76,363,636
Redeemable convertible preferred stock price per share			$ 1.375	$ 1.38			$ 1.38
Settlement of redeemable convertible preferred stock					$ 6,800,000
Redeemable convertible preferred stock			$ 47,500,000	$ 111,773,000			$ 111,773,000
Issuance Cost			300,000
Preferred Stock, Convertible, Conversion Price				$ 12.77
Proceeds from issuance of convertible preferred stock, net of issuance costs			$ 52,500,000
Series B \| Second Tranche
Class of Stock [Line Items]
Redeemable convertible preferred stock			38,181,818
Series B \| Third tranche
Class of Stock [Line Items]
Redeemable convertible preferred stock		38,181,818
Redeemable convertible preferred stock price per share		$ 1.375
Settlement of redeemable convertible preferred stock		$ 6,800,000
Redeemable convertible preferred stock		59,300,000
Proceeds from issuance of convertible preferred stock, net of issuance costs		52,500,000
Series B \| Maximum \| Third tranche
Class of Stock [Line Items]
Issuance Cost		$ 100,000
Series C
Class of Stock [Line Items]
Redeemable convertible preferred stock	65,454,544			65,454,544			65,454,544
Redeemable convertible preferred stock price per share	$ 1.375			$ 1.38			$ 1.38
Redeemable convertible preferred stock				$ 90,000,000			$ 90,000,000
Issuance Cost	$ 300,000
Price per share				$ 15.33
Proceeds from issuance of convertible preferred stock, net of issuance costs	$ 90,000,000

Related Party Transactions

6 Months Ended

Jun. 30, 2026

Related Party Transactions

11.

Related Party Transactions

Alamar Platform License Agreement

In June 2023, the Company issued 2,428,646 shares of its common stock to Alamar, an existing holder of the Company’s common stock, in exchange for the in-process research and development asset acquired under the Alamar Platform License Agreement (see Note 5). Alamar owned 800,632 shares of the Company’s common stock prior to this transaction, which was received by Alamar upon the Company’s incorporation in December 2022.

Alamar Lease Agreement

In June 2023, the Company entered into a lease agreement with Alamar, which was amended four times between October 2023 and October 2024, to lease approximately 10,422 square feet of office and laboratory spaces in Fremont, California. The lease expired in March 2025. The Company recognized expense of $0 and $0.2 million during the three and six months ended June 30, 2025, respectively.

Other Services Agreements

In June 2023, the Company entered into a Services Agreement (the “Services Agreement”) with Alamar, under which Alamar provides certain initial clerical, executive, and administrative services. In February 2024, the Company entered into a research services

agreement (together with the Services Agreement, the “Services Agreements”) for Alamar to provide certain research diagnostic services. Under both Services Agreements, the Company recognized expense of $0.2 million and less than $0.1 million during the three months ended June 30, 2026 and 2025, respectively. Under both Services Agreements, the Company recognized expense of $0.2 million and $0.1 million during the six months ended June 30, 2026 and 2025, respectively. The Company had an accounts payable balance of less than $0.1 million as of June 30, 2026 and December 31, 2025.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(7)(e)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2026

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):


	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Numerator:
Net loss	$	(20,687	)	$	(14,439	)	$	(39,343	)	$	(29,590	)
Accretion of redeemable convertible preferred stock to its redemption value		—			—			—			(271	)
Net loss attributable to common stockholders		(20,687	)		(14,439	)		(39,343	)		(29,861	)
Denominator:
Weighted average common shares outstanding		4,527,825			4,459,838			4,517,853			4,447,823
Less: Weighted average common shares subject to repurchase		(290,228	)		(564,801	)		(322,238	)		(596,699	)
Weighted average shares used in computing basic and diluted net loss per share		4,237,597			3,895,037			4,195,615			3,851,124
Net loss per share attributable to common stockholders, basic and diluted	$	(4.88	)	$	(3.71	)	$	(9.38	)	$	(7.75	)

Schedule of Diluted Net Loss Per Share

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:


	June 30,
	2026		2025
Redeemable convertible preferred stock		21,517,976		21,517,976
Options to purchase common stock		2,686,080		2,598,290
Unvested restricted stock awards		208,542		458,814
Unvested early exercised common stock options		24,076		48,151
Total		24,436,674		24,623,231

Fair Value Measurements

6 Months Ended

Jun. 30, 2026

Fair Value Disclosures [Abstract]

Fair Value Measurements

The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy which establishes three levels of inputs that may be used to measure fair value, as follows:

Level 1 — Observable inputs, such as quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

The Company recognizes transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs.

Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable.

The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands):


	June 30, 2026
	Level 1		Level 2		Level 3		Total
Assets:
Cash and cash equivalents
Money market funds	$	32,462	$	—	$	—	$	32,462

Marketable securities
U.S. Treasury notes		73,411		—		—		73,411
U.S. Treasury bills		8,892		—		—		8,892
Total financial assets	$	114,765	$	—	$	—	$	114,765


	December 31, 2025
	Level 1		Level 2		Level 3		Total
Assets:
Cash and cash equivalents
Money market funds	$	35,526	$	—	$	—	$	35,526
U.S. Treasury bills		—		2,485		—		2,485

Marketable securities
U.S. Treasury notes		82,397		—		—		82,397
U.S. Treasury bills		14,736		14,942		—		29,678
Total financial assets	$	132,659	$	17,427	$	—	$	150,086

The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):


	Preferred Stock Tranche Liability
Fair value as of December 31, 2024	$	6,638
Change in the fair value of Series B preferred stock tranche liability		170
Fair value upon settlement		(6,808	)
Fair value as of June 30, 2025	$	—

The fair value of the preferred stock tranche liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy (see Note 8).

There were no transfers in and out of Level 3 during the three and six months ended June 30, 2026 and 2025.

Share-based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	$ 692	$ 563	$ 1,378	$ 1,025
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	451	379	898	687
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation expense	$ 241	$ 184	$ 480	$ 338

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025
Numerator:
us-gaap:NetIncomeLoss	$ (20,687)	$ (18,656)	$ (14,439)	$ (15,151)	$ (39,343)	$ (29,590)
Accretion of redeemable convertible preferred stock to its redemption value	0		0		0	(271)
Net loss attributable to common stockholders	$ 20,687		$ 14,439		$ 39,343	$ 29,861
Denominator:
Weighted average common shares outstanding	4,527,825		4,459,838		4,517,853	4,447,823
Less: Weighted average common shares subject to repurchase	(290,228)		(564,801)		(322,238)	(596,699)
Weighted average shares used in computing basic net loss per share	4,237,597		3,895,037		4,195,615	3,851,124
Weighted average shares used in computing diluted net loss per share	4,237,597		3,895,037		4,195,615	3,851,124
Net loss per share attributable to common stockholders, - basic	$ (4.88)		$ (3.71)		$ (9.38)	$ (7.75)
Net loss per share attributable to common stockholders, - diluted	$ (4.88)		$ (3.71)		$ (9.38)	$ (7.75)

Net Loss Per Share - Schedule of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	24,436,674	24,623,231
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,686,080	2,598,290
Unvested Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	208,542	458,814
Unvested Early Exercised Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	24,076	48,151
Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	21,517,976	21,517,976

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 32,829	$ 40,193
Marketable securities	82,303	112,075
Prepaid expenses and other current assets	3,269	4,027
Total current assets	118,401	156,295
Restricted cash	404	404
Property and equipment, net	3,343	3,492
Operating lease right-of-use asset, net	3,578	4,373
Other non-current assets	2,622	1,329
Total assets	128,348	165,893
Current liabilities:
Accounts payable (including related party amounts of $32 and $39 at June, 2026 and December 31, 2025, respectively)	6,002	3,551
Accrued expenses and other current liabilities	4,575	5,535
Operating lease liability, current portion	2,038	1,921
Total current liabilities	12,615	11,007
Operating lease liability, net of current portion	2,288	3,341
Other non-current liabilities	678	755
Total liabilities	15,581	15,103
Commitments and contingencies (Note 6)
Stockholders' deficit:
Common stock - $0.0001 par value; 284,023,000 shares authorized at June 30, 2026 and December 31, 2025; 4,529,100 and 4,507,108 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	1	1
Additional paid-in capital	4,972	3,474
Accumulated other comprehensive (loss) income	(79)	99
Accumulated deficit	(150,353)	(111,010)
Total stockholders' deficit	(145,459)	(107,436)
Total liabilities, redeemable convertible preferred stock, and stockholders' deficit	128,348	165,893
Redeemable Convertible Preferred Stock [Member]
Current liabilities:
Redeemable convertible preferred stock - $0.0001 par value; 199,902,270 shares authorized, issued and outstanding at June 30, 2026 and December 31, 2025; aggregate liquidation preference of $255,850 at June 30, 2026 and December 31, 2025	$ 258,226	$ 258,226

Subsequent Events (Additional Information) (Details) - $ / shares		1 Months Ended	6 Months Ended
	Jul. 22, 2026	Jul. 31, 2026	Jun. 30, 2026	Dec. 31, 2025
Subsequent Event [Line Items]
Stock options available for future grant			80,817
Offering price			$ 4.07	$ 3.93
Reserved for future issuance			24,587,872	24,609,886
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock options available for future grant	1,642,700
Offering price	$ 17
Common stock for issuance of share-based compensation awards		4,900,000
Annual incremental percentage		1.00%
Subsequent Event [Member] \| 2026 Employee Stock Purchase Plan [Member]
Subsequent Event [Line Items]
Purchase price of fair value of common stock (in percent)		85.00%
Maximum offering period		27 months
Reserved for future issuance		410,000

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues [Abstract]
Total revenue	$ 450	$ 0	$ 450	$ 0
Operating Expenses [Abstract]
Research and development (including related party amounts of $178 and $34 for the three months ended June 30, 2026 and 2025, respectively, and $238 and $41 for the six months ended June 30, 2026 and 2025, respectively)	18,946	13,588	35,692	25,444
General and administrative (including related party amounts of $0 for the three months ended June 30, 2026 and 2025, and $0 and $239 for the six months ended June 30, 2026 and 2025, respectively)	3,307	3,032	6,516	7,280
Total operating expenses	22,253	16,620	42,208	32,724
Loss from operations	(21,803)	(16,620)	(41,758)	(32,724)
Other income (expense):
Interest income	1,141	2,041	2,467	3,167
Change in fair value of preferred stock tranche liability	0	0	0	(170)
Other income (expense), net	(25)	140	(52)	137
Total other income (expense), net	1,116	2,181	2,415	3,134
Net loss	(20,687)	(14,439)	(39,343)	(29,590)
Less: Accretion of redeemable convertible preferred stock to its redemption value	0	0	0	(271)
Net loss attributable to common stockholders	$ (20,687)	$ (14,439)	$ (39,343)	$ (29,861)
Net loss per share attributable to common stockholders, - basic	$ (4.88)	$ (3.71)	$ (9.38)	$ (7.75)
Net loss per share attributable to common stockholders, - diluted	$ (4.88)	$ (3.71)	$ (9.38)	$ (7.75)
Weighted-average common shares outstanding, basic	4,237,597	3,895,037	4,195,615	3,851,124
Weighted-average common shares outstanding, diluted	4,237,597	3,895,037	4,195,615	3,851,124
Other comprehensive loss:
Unrealized loss on available-for-sale marketable securities, net	$ (52)	$ (52)	$ (178)	$ (76)
Net loss and other comprehensive loss	(20,739)	(14,491)	(39,521)	(29,666)
Collaboration Revenue [Member]
Revenues [Abstract]
Total revenue	$ 450	$ 0	$ 450	$ 0

Commitments and Contingencies

6 Months Ended

Jun. 30, 2026

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Leases

The Company leases its office, laboratory and storage spaces in San Carlos, California under a non-cancelable operating lease expiring on June 30, 2028.

As of June 30, 2026, the future minimum lease commitments under the operating lease were as follows (in thousands):


(in thousands)
Year ended December 31,
2026 (remainder of the year)	$	1,134
2027		2,333
2028		1,200
Total future minimum lease payments	$	4,667
Less: Imputed interest		(341	)
Present value of operating lease liabilities	$	4,326

Legal Contingencies

From time to time, the Company may become involved in legal proceedings arising from the ordinary course of business. The Company records a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by the Company is required to determine both probability and the estimated amount. Management is currently not aware of any legal matters that could have a material adverse effect on the Company’s financial position, results of operations or cash flows.

Indemnification Agreements

In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors’ and officers’ liability insurance.

Balance Sheet Components

6 Months Ended

Jun. 30, 2026

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

Marketable Securities

Marketable securities, which are classified as available-for-sale, consisted of the following as of June 30, 2026 and December 31, 2025 (in thousands):


	June 30, 2026
	Amortized Cost		Unrealized Gain		Unrealized Loss			Estimated Fair Value
U.S. Treasury notes	$	73,493	$	1	$	(83	)	$	73,411
U.S. Treasury bills		8,896		—		(4	)		8,892
Available-for-sale marketable securities	$	82,389	$	1	$	(87	)	$	82,303


	December 31, 2025
	Amortized Cost		Unrealized Gain		Unrealized Loss			Estimated Fair Value
U.S. Treasury notes	$	82,309	$	89	$	(1	)	$	82,397
U.S. Treasury bills		29,667		11		—			29,678
Available-for-sale marketable securities	$	111,976	$	100	$	(1	)	$	112,075

All marketable securities held as of June 30, 2026 and December 31, 2025 had contractual maturities of less than one year.

As of June 30, 2026 and December 31, 2025, no significant facts or circumstances were present to indicate a deterioration in the creditworthiness of the issuers of the marketable securities, and the Company has no requirement or intention to sell these securities before maturity or recovery of their amortized cost basis. The Company considered the current and expected future economic and market conditions and determined that its investments were not significantly impacted. For all securities with a fair value less than their amortized cost basis, the Company determined the decline in fair value below amortized cost basis to be immaterial and non-credit related, and therefore no allowance for losses has been recorded. For the three and six months ended June 30, 2026 and 2025, the Company did not recognize any impairment losses on its investments.

As of June 30, 2026 and December 31, 2025, accrued interest receivable was $0.9 million and $0.9 million, respectively, which were recorded in the prepaid expenses and other current assets on the condensed consolidated balance sheets.

Property and Equipment, Net

Property and equipment, net consists of the following (in thousands, except years):


	Estimated Useful Life
	(in years)	June 30, 2026			December 31, 2025
Laboratory equipment	5	$	4,210		$	3,907
Computer equipment and software	3		245			245
Furniture and fixtures	7		273			273
Leasehold improvements	Lesser of estimated useful lives of 15 years or remaining lease term		136			136
Construction in progress			64			28
			4,928			4,589

Less: Accumulated depreciation			(1,585	)		(1,097	)
Property and equipment, net		$	3,343		$	3,492

Depreciation and amortization expense for the three months ended June 30, 2026 and 2025 was $0.2 million and $0.2 million, respectively. Depreciation and amortization expense for the six months ended June 30, 2026 and 2025 was $0.5 million and $0.4 million, respectively.

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	June 30, 2026		December 31, 2025
Accrued compensation	$	1,905	$	3,103
Accrued research and development expenses		2,549		1,069
Accrued professional fees		29		556
Contract liability		—		450
Other accrued expenses and current liabilities		92		357
Total accrued expenses and other current liabilities	$	4,575	$	5,535

Employee Benefit Plans	6 Months Ended
Employee Benefit Plans	Jun. 30, 2026
Disclosure Text Block [Abstract]
Employee Benefit Plans	13. Employee Benefit Plans The Company sponsors a qualified 401(k) defined contribution plan (the “401(k) Plan”) covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. The Company’s contributions to the 401(k) Plan were $0.1 million and less than $0.1 million for the three months ended June 30, 2026 and 2025, respectively. The Company’s contributions to the 401(k) Plan were $0.2 million and $0.1 million for the six months ended June 30, 2026 and 2025, respectively.

Fair Value Measurements (Additional Information) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Fair Value Disclosures [Abstract]
Transfers in and out of level 3	$ 0	$ 0	$ 0	$ 0

Organization and Nature of the Business (Additional Information) (Details) - USD ($) $ / shares in Units, $ in Thousands			6 Months Ended
	Aug. 06, 2026	Aug. 04, 2026	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Product Information [Line Items]
Common Stock Issued			4,529,100		4,507,108
Common stock, par value			$ 0.0001		$ 0.0001
Gross proceeds of shares			$ 42	$ 143
Authorized shares of common stock			284,023,000		284,023,000
Preferred stock, par value			$ 0.0001		$ 0.0001
Preferred stock, shares authorized			199,902,270		199,902,270
Accumulated deficit			$ (150,353)		$ (111,010)
Subsequent Event [Member]
Product Information [Line Items]
Proceeds from issuance of initial public offering	$ 305,400
Initial Public Offering \| Subsequent Event [Member]
Product Information [Line Items]
Common Stock Issued		19,550,000
Common stock, par value	$ 0.0001	$ 17
Gross proceeds of shares		$ 332,400
Preferred stock converted into common shares	21,517,976
Authorized shares of common stock	500,000,000
Preferred stock, par value	$ 0.0001
Preferred stock, shares authorized	10,000,000
Initial Public Offering \| Maximum \| Subsequent Event [Member]
Product Information [Line Items]
Additional shares		2,550,000
Liquidity
Product Information [Line Items]
Accumulated deficit			(150,400)
Cash , cash equivalents and marketable securities			$ 115,100
Liquidity description			The Company will continue to require substantial additional capital in the future to support further development of its product candidates and maintain its operations. Until such time as it can generate significant revenue from product sales, if ever, the Company expects to raise additional capital through equity or debt financings, collaborations, licensing arrangements or other sources. Management believes that the Company’s existing cash, cash equivalents and marketable securities, together with the net proceeds from the IPO, will be sufficient to fund the Company’s planned operations for at least 12 months from the date of the issuance of these condensed consolidated financial statements.

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2026
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements and related disclosures are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The Company’s unaudited condensed consolidated financial statements include the accounts of its subsidiaries, and all intercompany transactions were eliminated upon consolidation. Prior to July 2025, the Company had no subsidiaries. Reverse Stock Split On July 22, 2026, the board of directors approved, and on July 29, 2026, the Company effected, a reverse stock split of the shares of the Company’s outstanding common stock at a ratio of 1-for-9.29 (the “Reverse Stock Split”). The number of authorized shares and par value per share were not adjusted as a result of the Reverse Stock Split. All references to shares, options to purchase common stock, share amounts, per share amounts, and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. The shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. In addition, the conversion ratios for each series of the Company’s redeemable convertible preferred stock, which automatically converted into shares of common stock upon the closing of the Company’s IPO of common stock, were proportionally adjusted. No fractional shares were issued in connection with the Reverse Stock Split. Unaudited Interim Financial Information The condensed consolidated balance sheet as of December 31, 2025 was derived from the Company’s audited consolidated financial statements but does not contain all of the footnote disclosures from the consolidated financial statements. The accompanying unaudited interim condensed consolidated financial statements as of June 30, 2026 and for the three and six months ended June 30, 2026 and 2025, have been prepared by the Company, pursuant to the rules and regulations of the SEC for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. Accordingly, these unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2025 and notes thereto, included in the Company’s final prospectus for the IPO filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s condensed consolidated financial position as of June 30, 2026 and condensed consolidated results of operations, condensed consolidated statements of redeemable convertible preferred stock and stockholders’ deficit for the three and six months ended June 30, 2026 and 2025 and condensed consolidated cash flows for the six months ended June 30, 2026 and 2025 have been made. The results of operations for the three and six months ended June 30, 2026 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2026. Other than the policies noted below, there have been no changes from the significant accounting policies and estimates disclosed in Note 2 to the Company’s audited consolidated financial statements for the year ended December 31, 2025 included in the Company’s final prospectus filed with the SEC pursuant to Rule 424(b)(4) on August 5, 2026. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include the fair value of marketable securities, the fair values of preferred stock tranche liabilities, the fair value of common stock, valuation of deferred tax assets, incremental borrowing rate for leases, accruals for research and development activities and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Segments Operating segments are defined as components of an entity for which separate financial information is available and regularly utilized by the Chief Operating Decision Maker (“CODM”) to assess the Company’s performance for capital and resource allocation decisions. The Company’s CODM is its Chief Executive Officer, who reviews such financial information on an aggregate company-level basis (see Note 14). The Company has determined it operates as a single operating segment and has one reportable segment, which is the research and development of therapeutic products in the fields of immune-mediated diseases. Revenue is generated exclusively from transactions with a party located in the United States of America. All long-lived assets are maintained in the United States. Concentration of Credit Risk and of Significant Suppliers Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and restricted cash. The Company is exposed to credit risk from its deposits of cash and cash equivalents in excess of amounts insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company has not experienced any losses on its deposits of cash and cash equivalents during the periods presented. The Company invests in money market funds, U.S. Treasury bills and notes, and other short-term fixed income securities which can be subject to certain credit risks. The Company mitigates these risks by investing in high-grade instruments, limiting its exposure to any one issuer and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its financial instruments. The Company is dependent on third-party manufacturers to supply materials for research and development activities for the Company’s pipeline products, including preclinical and clinical studies and testing, and manufacturing activities. In particular, the Company relies on a small number of manufacturers for the supply of drug substance and drug product materials for its clinical assets. The Company’s preclinical and clinical studies and testing and manufacturing activities could be adversely affected by a significant interruption in the supply of materials from its suppliers. Risks and Uncertainties The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance and reporting. The Company’s product candidates are still in either preclinical or clinical development and, to date, none of the Company’s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Deferred Offering Costs Deferred offering costs, consisting of legal, accounting and other third-party fees directly relating to in-process equity financings or offerings are capitalized. The deferred offering costs will be offset against offering proceeds upon the completion of the financing or the offering. As of June 30, 2026 and December 31, 2025, deferred offering costs of $2.5 million and $1.2 million, respectively, were capitalized and recorded as non-current assets on the condensed consolidated balance sheets. Upon closing the IPO in August 2026, all deferred offering costs were charged against the proceeds from the IPO and recorded in stockholders’ deficit as a reduction of additional paid-in capital. Net Loss Per Share Attributable to Common Stockholders Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Net loss attributable to common stockholders is computed as net loss less accretion of redeemable convertible preferred stock. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, unvested restricted stock awards and stock options are considered to be potentially dilutive securities. Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock and unvested restricted stock awards are considered participating securities. The redeemable convertible preferred stock does not have a contractual obligation to share in the Company’s losses, and unvested restricted stock awards are considered contingently issuable shares for accounting purposes. Because the Company has reported a net loss for the periods presented, the diluted net loss per share of common stock is the same as basic net loss per common share for the periods presented. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) under its Accounting Standards Codification (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”) and adopts new or revised accounting standards on the dates applicable to nonpublic entities unless it adopts such standards early. Accounting Pronouncements Not Yet Adopted In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (Topic 220), requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual periods beginning after December 15, 2027. The requirements of ASU 2024-03 may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting ASU 2024-03 on its condensed consolidated financial statements and disclosures.

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2025 USD ($)
Series B Preferred Stock [Member]
Temporary equity tranche liability	$ 6,808
Issuance Cost	35
Series C Preferred Stock [Member]
Issuance Cost	$ 271

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (unaudited) - USD ($) $ in Thousands	Total	Redeemable Convertible Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Series C Preferred Stock [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Shares, Outstanding, Beginning Balance at Dec. 31, 2024					4,425,956
Beginning Balance, Value at Dec. 31, 2024	$ (46,825)				$ 1	$ 3,490		$ (50,383)	$ 67
Redeemable Convertible Preferred Stock Shares, Beginning Balance at Dec. 31, 2024		96,265,908
Redeemable Convertible Preferred Stock Value, Beginning Balance at Dec. 31, 2024		$ 108,953
Stock-based compensation expense	462					462
Issuance of common stock upon exercise of stock options, Shares					23,788
Issuance of common stock upon exercise of stock options, Value	45					45
Redeemable Convertible Preferred Stock, Shares			38,181,818	65,454,544
Redeemable Convertible Preferred Stock Value			$ 59,273	$ 89,729
Unrealized loss on marketable securities, net	(24)								(24)
Accretion of redeemable convertible preferred stock to its redemption value				$ 271
Accretion of redeemable convertible preferred stock to its redemption value	(271)						$ (271)
us-gaap:NetIncomeLoss	(15,151)							(15,151)
Shares, Outstanding, Ending Balance at Mar. 31, 2025					4,449,744
Ending Balance, Value at Mar. 31, 2025	(61,764)				$ 1	3,726		(65,534)	43
Redeemable Convertible Preferred Stock Shares, Ending Balance at Mar. 31, 2025		199,902,270
Redeemable Convertible Preferred Stock Value, Ending Balance at Mar. 31, 2025		$ 258,226
Shares, Outstanding, Beginning Balance at Dec. 31, 2024					4,425,956
Beginning Balance, Value at Dec. 31, 2024	(46,825)				$ 1	3,490		(50,383)	67
Redeemable Convertible Preferred Stock Shares, Beginning Balance at Dec. 31, 2024		96,265,908
Redeemable Convertible Preferred Stock Value, Beginning Balance at Dec. 31, 2024		$ 108,953
Accretion of redeemable convertible preferred stock to its redemption value	271
Accretion of redeemable convertible preferred stock to its redemption value	(271)
us-gaap:NetIncomeLoss	(29,590)
Shares, Outstanding, Ending Balance at Jun. 30, 2025					4,485,996
Ending Balance, Value at Jun. 30, 2025	(75,527)				$ 1	4,454		(79,973)	(9)
Redeemable Convertible Preferred Stock Shares, Ending Balance at Jun. 30, 2025		199,902,270
Redeemable Convertible Preferred Stock Value, Ending Balance at Jun. 30, 2025		$ 258,226
Shares, Outstanding, Beginning Balance at Mar. 31, 2025					4,449,744
Beginning Balance, Value at Mar. 31, 2025	(61,764)				$ 1	3,726		(65,534)	43
Redeemable Convertible Preferred Stock Shares, Beginning Balance at Mar. 31, 2025		199,902,270
Redeemable Convertible Preferred Stock Value, Beginning Balance at Mar. 31, 2025		$ 258,226
Stock-based compensation expense	563					563
Issuance of common stock upon exercise of stock options, Shares					36,252
Issuance of common stock upon exercise of stock options, Value	98					98
Vesting of early exercised stock options	67					67
Unrealized loss on marketable securities, net	(52)								(52)
Accretion of redeemable convertible preferred stock to its redemption value	0
us-gaap:NetIncomeLoss	(14,439)							(14,439)
Shares, Outstanding, Ending Balance at Jun. 30, 2025					4,485,996
Ending Balance, Value at Jun. 30, 2025	(75,527)				$ 1	4,454		(79,973)	(9)
Redeemable Convertible Preferred Stock Shares, Ending Balance at Jun. 30, 2025		199,902,270
Redeemable Convertible Preferred Stock Value, Ending Balance at Jun. 30, 2025		$ 258,226
Shares, Outstanding, Beginning Balance at Dec. 31, 2025					4,507,108
Beginning Balance, Value at Dec. 31, 2025	$ (107,436)				$ 1	3,474		(111,010)	99
Redeemable Convertible Preferred Stock Shares, Beginning Balance at Dec. 31, 2025	199,902,270	199,902,270
Redeemable Convertible Preferred Stock Value, Beginning Balance at Dec. 31, 2025	$ 258,226	$ 258,226
Stock-based compensation expense	686					686
Issuance of common stock upon exercise of stock options, Shares					3,933
Issuance of common stock upon exercise of stock options, Value	11					11
Vesting of early exercised stock options	6					6
Unrealized loss on marketable securities, net	(126)								(126)
us-gaap:NetIncomeLoss	(18,656)							(18,656)
Shares, Outstanding, Ending Balance at Mar. 31, 2026					4,511,041
Ending Balance, Value at Mar. 31, 2026	(125,515)				$ 1	4,177		(129,666)	(27)
Redeemable Convertible Preferred Stock Shares, Ending Balance at Mar. 31, 2026		199,902,270
Redeemable Convertible Preferred Stock Value, Ending Balance at Mar. 31, 2026		$ 258,226
Shares, Outstanding, Beginning Balance at Dec. 31, 2025					4,507,108
Beginning Balance, Value at Dec. 31, 2025	$ (107,436)				$ 1	3,474		(111,010)	99
Redeemable Convertible Preferred Stock Shares, Beginning Balance at Dec. 31, 2025	199,902,270	199,902,270
Redeemable Convertible Preferred Stock Value, Beginning Balance at Dec. 31, 2025	$ 258,226	$ 258,226
Issuance of common stock upon exercise of stock options, Shares	21,992
Accretion of redeemable convertible preferred stock to its redemption value	$ 0
Accretion of redeemable convertible preferred stock to its redemption value	0
us-gaap:NetIncomeLoss	(39,343)
Shares, Outstanding, Ending Balance at Jun. 30, 2026					4,529,100
Ending Balance, Value at Jun. 30, 2026	(145,459)				$ 1	4,972		(150,353)	(79)
Redeemable Convertible Preferred Stock Shares, Ending Balance at Jun. 30, 2026		199,902,270
Redeemable Convertible Preferred Stock Value, Ending Balance at Jun. 30, 2026	258,226	$ 258,226
Shares, Outstanding, Beginning Balance at Mar. 31, 2026					4,511,041
Beginning Balance, Value at Mar. 31, 2026	(125,515)				$ 1	4,177		(129,666)	(27)
Redeemable Convertible Preferred Stock Shares, Beginning Balance at Mar. 31, 2026		199,902,270
Redeemable Convertible Preferred Stock Value, Beginning Balance at Mar. 31, 2026		$ 258,226
Stock-based compensation expense	692					692
Issuance of common stock upon exercise of stock options, Shares					18,059
Issuance of common stock upon exercise of stock options, Value	31					31
Vesting of early exercised stock options	72					72
Unrealized loss on marketable securities, net	(52)								(52)
Accretion of redeemable convertible preferred stock to its redemption value	0
us-gaap:NetIncomeLoss	(20,687)							(20,687)
Shares, Outstanding, Ending Balance at Jun. 30, 2026					4,529,100
Ending Balance, Value at Jun. 30, 2026	(145,459)				$ 1	$ 4,972		$ (150,353)	$ (79)
Redeemable Convertible Preferred Stock Shares, Ending Balance at Jun. 30, 2026		199,902,270
Redeemable Convertible Preferred Stock Value, Ending Balance at Jun. 30, 2026	$ 258,226	$ 258,226

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Statement [Table]
Accounts payable including related party	$ 32	$ 39
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	199,902,270	199,902,270
Preferred stock, shares issued	199,902,270	199,902,270
Preferred stock, shares outstanding	199,902,270	199,902,270
Aggregate liquidation preference	$ 255,850	$ 255,850
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	284,023,000	284,023,000
Common stock, shares issued	4,529,100	4,507,108
Common stock, shares outstanding	4,529,100	4,507,108

Redeemable Convertible Preferred Stock (Tables)

6 Months Ended

Jun. 30, 2026

Equity [Abstract]

Summary of Redeemable Convertible Preferred Stock

As of June 30, 2026 and December 31, 2025, redeemable convertible preferred stock consisted of the following (in thousands, except share and price data):


	June 30, 2026 and December 31, 2025
	Shares Authorized		Original Issue Price		Shares Issued and Outstanding		Carrying Value		Liquidation Value
Series A-1		30,425,000	$	1.00		30,425,000	$	26,046	$	30,425
Series A-2		27,659,090	$	1.10		27,659,090		30,407		30,425
Series B		76,363,636	$	1.38		76,363,636		111,773		105,000
Series C		65,454,544	$	1.38		65,454,544		90,000		90,000
		199,902,270				199,902,270	$	258,226	$	255,850

- Definition

Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References + Details

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2026

Fair Value Disclosures [Abstract]

Schedule of Fair Value of the Company's Financial Assets and Liabilities Measured on a Recurring Basis

The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands):


	June 30, 2026
	Level 1		Level 2		Level 3		Total
Assets:
Cash and cash equivalents
Money market funds	$	32,462	$	—	$	—	$	32,462

Marketable securities
U.S. Treasury notes		73,411		—		—		73,411
U.S. Treasury bills		8,892		—		—		8,892
Total financial assets	$	114,765	$	—	$	—	$	114,765


	December 31, 2025
	Level 1		Level 2		Level 3		Total
Assets:
Cash and cash equivalents
Money market funds	$	35,526	$	—	$	—	$	35,526
U.S. Treasury bills		—		2,485		—		2,485

Marketable securities
U.S. Treasury notes		82,397		—		—		82,397
U.S. Treasury bills		14,736		14,942		—		29,678
Total financial assets	$	132,659	$	17,427	$	—	$	150,086

Schedule of Changes in the Fair Value

The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):


	Preferred Stock Tranche Liability
Fair value as of December 31, 2024	$	6,638
Change in the fair value of Series B preferred stock tranche liability		170
Fair value upon settlement		(6,808	)
Fair value as of June 30, 2025	$	—

Common Stock

6 Months Ended

Jun. 30, 2026

Stockholders' Equity Note [Abstract]

Common Stock

As of June 30, 2026, the Company was authorized to issue 284,023,000 shares of common stock with a par value of $0.0001 per share. There were 4,529,100 shares of common stock issued and outstanding as of June 30, 2026.

The Company had reserved common stock, on an as-converted basis, for future issuance as follows:


	June 30, 2026		December 31, 2025
Conversion of redeemable convertible preferred shares		21,517,976		21,517,976
Stock options issued and outstanding		2,686,080		2,642,930
Stock options available for future grant		383,816		448,980
Total common stock reserved		24,587,872		24,609,886

Balance Sheet Components (Tables)

6 Months Ended

Jun. 30, 2026

Balance Sheet Related Disclosures [Abstract]

Schedule of Marketable Securities Classified as Available-for-Sale

Marketable securities, which are classified as available-for-sale, consisted of the following as of June 30, 2026 and December 31, 2025 (in thousands):


	June 30, 2026
	Amortized Cost		Unrealized Gain		Unrealized Loss			Estimated Fair Value
U.S. Treasury notes	$	73,493	$	1	$	(83	)	$	73,411
U.S. Treasury bills		8,896		—		(4	)		8,892
Available-for-sale marketable securities	$	82,389	$	1	$	(87	)	$	82,303


	December 31, 2025
	Amortized Cost		Unrealized Gain		Unrealized Loss			Estimated Fair Value
U.S. Treasury notes	$	82,309	$	89	$	(1	)	$	82,397
U.S. Treasury bills		29,667		11		—			29,678
Available-for-sale marketable securities	$	111,976	$	100	$	(1	)	$	112,075

Schedule Of Property and Equipment Net Consists

Property and equipment, net consists of the following (in thousands, except years):


	Estimated Useful Life
	(in years)	June 30, 2026			December 31, 2025
Laboratory equipment	5	$	4,210		$	3,907
Computer equipment and software	3		245			245
Furniture and fixtures	7		273			273
Leasehold improvements	Lesser of estimated useful lives of 15 years or remaining lease term		136			136
Construction in progress			64			28
			4,928			4,589

Less: Accumulated depreciation			(1,585	)		(1,097	)
Property and equipment, net		$	3,343		$	3,492

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	June 30, 2026		December 31, 2025
Accrued compensation	$	1,905	$	3,103
Accrued research and development expenses		2,549		1,069
Accrued professional fees		29		556
Contract liability		—		450
Other accrued expenses and current liabilities		92		357
Total accrued expenses and other current liabilities	$	4,575	$	5,535

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

+ Details

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Research and development expense including related party	$ 18,946	$ 13,588	$ 35,692	$ 25,444
General and administrative including related party	3,307	3,032	6,516	7,280
Related Party [Member]
Research and development expense including related party	178	34	238	41
General and administrative including related party	$ 0	$ 0	$ 0	$ 239

Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2026

Single Reportable Segment

Segment Reporting [Line Items]

Segment Reporting

the following table provides disaggregated amounts that comprised research and development expenses (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
External costs
Clinical, manufacturing, and preclinical services	$	13,971	$	9,206	$	25,866	$	17,216
Professional consulting services		889		666		1,507		1,194
Consumables and other research and development costs		728		844		1,480		1,397
Internal costs
Personnel-related costs		2,923		2,561		5,940		5,073
Facilities and overhead costs		435		311		899		564
Total research and development expenses	$	18,946	$	13,588	$	35,692	$	25,444

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (j)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

Employee Benefit Plans (Additional Information) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Defined Benefit Plan [Abstract]
Company's contributions to the 401(k) plan	$ 0.1	$ 0.1	$ 0.2	$ 0.1

Net Loss Per Share

6 Months Ended

Jun. 30, 2026

Earnings Per Share [Abstract]

Net Loss Per Share

12.

Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):


	Three Months Ended June 30,						Six Months Ended June 30,
	2026			2025			2026			2025
Numerator:
Net loss	$	(20,687	)	$	(14,439	)	$	(39,343	)	$	(29,590	)
Accretion of redeemable convertible preferred stock to its redemption value		—			—			—			(271	)
Net loss attributable to common stockholders		(20,687	)		(14,439	)		(39,343	)		(29,861	)
Denominator:
Weighted average common shares outstanding		4,527,825			4,459,838			4,517,853			4,447,823
Less: Weighted average common shares subject to repurchase		(290,228	)		(564,801	)		(322,238	)		(596,699	)
Weighted average shares used in computing basic and diluted net loss per share		4,237,597			3,895,037			4,195,615			3,851,124
Net loss per share attributable to common stockholders, basic and diluted	$	(4.88	)	$	(3.71	)	$	(9.38	)	$	(7.75	)


	June 30,
	2026		2025
Redeemable convertible preferred stock		21,517,976		21,517,976
Options to purchase common stock		2,686,080		2,598,290
Unvested restricted stock awards		208,542		458,814
Unvested early exercised common stock options		24,076		48,151
Total		24,436,674		24,623,231